Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: DaVita is a leading provider of dialysis services and related products. The company operates a network of dialysis centers and provides ancillary services including pharmacy, vascular access, and home infusion therapy. As of September 30, 2007, the company had approximately 106.7 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Net Operating Revenues | $1,318,381 | $3,909,282 |
| Operating Income | $212,412 | $666,946 |
| Net Income | $94,455 | $296,061 |
| Diluted Earnings Per Share | $0.88 | $2.76 |
| Cash Provided by Operating Activities | N/A (Quarterly not provided) | $309,710 |
| Total Debt (Long-term + Current) | $3,705,297 | $3,705,297 |
| Cash and Cash Equivalents | $391,300 | $391,300 |
Operational Metrics (Nine Months Ended Sep 30, 2007):
- Total Dialysis Treatments: 11,335,453
- Average Dialysis Revenue per Treatment: $336
- Patient Care Costs as % of Revenue: 68.1%
Material Changes vs. Prior Period
Revenue Growth: Net operating revenues increased 6.6% in the third quarter and 8.3% for the nine months ended September 30, 2007, compared to the same periods in 2006. This growth was driven by a 5.0% increase in the number of treatments and a 1.0% to 2.0% increase in average revenue per treatment, partially offset by lower government reimbursement for pharmaceuticals.
Profitability: Operating income for the nine months ended September 30, 2007, increased to $666.9 million from $550.9 million in the prior year period. Net income rose to $296.1 million from $215.6 million.
Expense Trends:
- Patient Care Costs: Decreased as a percentage of revenue to 68.1% for the nine months (from 69.8% in 2006), aided by insurance settlements and lower benefit costs, though labor costs increased.
- Debt Expense: Decreased by approximately $12 million for the nine months compared to 2006 due to principal prepayments and lower interest rate margins.
- Valuation Gains: The company recorded a net valuation gain of $55.3 million in the second quarter of 2007 (included in the nine-month total) related to the termination of purchase obligations for dialysis machines under the Alliance and Product Supply Agreement with Gambro due to an FDA import ban.
Acquisitions: During the first nine months of 2007, the company acquired 10 dialysis centers and purchased 85% of HomeChoice Partners (HCP) for approximately $70.2 million.
Guidance, Outlook, and Risks
Management Guidance:
- Q4 2007 Operating Income: Expected to be in the range of $190 million to $200 million.
- Full Year 2007 Operating Income: Narrowed to a range of $800 million to $810 million.
- 2008 Operating Income: Projected range of $790 million to $850 million (excluding potential Medicare legislation impact), with management noting a higher likelihood of results at the lower end of the range due to "unusual earnings uncertainty."
- Capital Expenditures: Expected to spend $110-$120 million on maintenance/IT and $200-$220 million on new center development and acquisitions (excluding HCP) in 2007.
Key Risks and Contingencies:
- Government Investigations: The company is subject to multiple ongoing investigations by the U.S. Attorney's Offices (Missouri, New York, Texas) and the Office of Inspector General regarding billing practices, specifically related to EPO (erythropoietin) administration, pharmaceutical relationships, and joint ventures. These could result in substantial penalties or exclusion from Medicare/Medicaid.
- Commercial Payor Rates: Approximately 35% of revenue comes from commercial payors. Management notes downward pressure on these rates and expects them to be materially lower in the future, which could significantly impact profitability.
- Medicare Policy Changes: Risks associated with potential "bundling" of separately billable services (like EPO) into the composite rate, which could reduce overall reimbursement.
- Regulatory Compliance: Extensive scrutiny of anemia management practices and physician referral relationships (Stark II and Anti-Kickback laws).
Investor Verification Checklist
- Regulatory Exposure: Verify the status and potential financial impact of the ongoing U.S. Attorney and OIG investigations regarding EPO billing and joint venture arrangements.
- Commercial Rate Trends: Monitor the outcome of negotiations with commercial payors, as a significant decline in these rates poses a material risk to margins.
- Medicare Bundling: Assess the likelihood and timing of CMS bundling EPO and other pharmaceuticals into the composite dialysis rate.
- Debt Covenants: Confirm continued compliance with financial covenants, specifically the leverage ratio (currently less than 3.5:1), to avoid restrictions on capital expenditures or dividends.
- Integration of HCP: Evaluate the financial performance and integration progress of the HomeChoice Partners acquisition.
- Valuation Gains: Note that the $55.3 million valuation gain from the Gambro agreement is a non-cash, non-recurring item that boosted operating income in the prior quarter.